Comment
. 2005 Feb 1;23(4):923; author reply 923-4.
doi: 10.1200/JCO.2005.05.111.
Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor-targeted therapy?
- PMID: 15681544
- DOI: 10.1200/JCO.2005.05.111
Item in Clipboard
Comment
Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor-targeted therapy?
J Clin Oncol.
.
No abstract available
Comment on
-
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.J Clin Oncol. 2004 Apr 1;22(7):1201-8. doi: 10.1200/JCO.2004.10.182. Epub 2004 Mar 1. J Clin Oncol. 2004. PMID: 14993230 Clinical Trial.
Similar articles
-
Introduction: Emerging therapies with epidermal growth factor receptor-targeted agents in colorectal cancer.Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S60-1. Clin Colorectal Cancer. 2005. PMID: 16336750 No abstract available.
-
Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742. Pharmacotherapy. 2008. PMID: 18503402 Review.
-
Panitumumab (Vectibix) for metastatic colorectal cancer.Med Lett Drugs Ther. 2007 Apr 23;49(1259):35-6. Med Lett Drugs Ther. 2007. PMID: 17450113 No abstract available.
-
Cetuximab for colorectal cancer.N Engl J Med. 2008 Mar 13;358(11):1196; author reply 1196-7. N Engl J Med. 2008. PMID: 18340663 No abstract available.
-
Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.Oncology (Williston Park). 2007 Jul;21(8):964-70; discussion 970, 974, 976-7. Oncology (Williston Park). 2007. PMID: 17715697 Review.
Cited by
-
Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.World J Gastroenterol. 2007 Nov 28;13(44):5888-901. doi: 10.3748/wjg.v13.i44.5888. World J Gastroenterol. 2007. PMID: 17990354 Free PMC article. Review.
-
HER2 expression as a potential marker for response to therapy targeted to the EGFR.Br J Cancer. 2006 Apr 24;94(8):1144-53. doi: 10.1038/sj.bjc.6603078. Br J Cancer. 2006. PMID: 16622439 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
